(UroToday.com) The 2026 North Central Section of the AUA annual meeting featured a prostate cancer session and a presentation ...

The 2026 North Central Section of the AUA annual meeting featured a urothelial carcinoma session and a presentation by Dr.

The 2026 North Central Section of the AUA annual meeting featured a bladder cancer session and a presentation by Dr. Kaitlin Davis discussing regional disparities in bladder cancer mortality rates.

To evaluate the hypothesis that infectious adverse events following prostatic artery embolization (PAE) are comparable to those following other treatment options for benign prostatic hyperplasia (BPH) ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Current clinical risk stratification for determining neoadjuvant chemotherapy (NAC) usage in nonmetastatic upper tract urothelial carcinoma (UTUC) is frequently inaccurate. This uncertainty leads to ...

Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without ...

Chromophobe renal cell carcinoma (chRCC) is a rare subtype of kidney cancer with biological and clinical features that differ significantly from clear cell renal cell carcinoma (ccRCC). While adjuvant ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.